The effect of adjuvant systemic therapy on prognostic impact of polymorphisms

<p><b>Copyright information:</b></p><p>Taken from "Association of codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients"</p><p>http://breast-cancer-research.com/content/9/3/R34</p><p>Breast Cancer Research 2007;9(3):R34-R34.</p><p>Published online 30 May 2007</p><p>PMCID:PMC1929098.</p><p></p> codon 72 and adjuvant chemotherapy alone (= 137); codon 72 and adjuvant chemotherapy with or without hormonal therapy (= 281); codon 72 and adjuvant hormonal therapy alone (= 195); codon 72 and no adjuvant systemic therapy (= 77); SNP309 and adjuvant tamoxifen with or without luteinizing hormone-releasing hormone analog (= 185). DFS, disease-free survival

The names of the ethics committees/institutional review boards.

(DOCX)</p

Patients’ flow chart.

HRQOL, health-related quality of life.</p

Linear spline MID estimates based on the anchor method.

Linear spline MID estimates based on the anchor method.</p

TREND statement checklist.

(DOC)</p

FACT-ES score cumulative distribution functions by clinical benefit status at 1 month and 3 months.

(a) The cumulative distribution functions for the FACT-ES total score according to the clinical benefit status at 1 month. The vertical dotted lines indicate the MID thresholds. (b) The cumulative distribution functions for the FACT-ES total score according to the clinical benefit status at 3 months. The vertical dotted lines indicate the MID thresholds. FACT-ES, Functional Assessment of Cancer Therapy-Endocrine Symptoms; MID, minimally important difference.</p

Summary of HRQOL scores and MID estimates based on the distribution method.

Summary of HRQOL scores and MID estimates based on the distribution method.</p

Study protocol (English version).

(PDF)</p

Patient characteristics at baseline (n = 47).

Patient characteristics at baseline (n = 47).</p

Study protocol (Japanese version).

(PDF)</p